ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9637
-0.12%
Brent Oil
83.095
-0.04%
Bitcoin
63,835.44
-0.26%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. GeoVax Labs Inc (GOVX)

  7. GeoVax Labs Inc (GOVX) Noticias

GOVX GeoVax Labs Inc

1.61
0.19 (13.38%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
GeoVax Labs Inc GOVX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.19 13.38% 1.61 23:00:05
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.42 1.42 1.70 1.61 1.42
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
04/4/202411:30GLOBEGeoVax Presents Data on GEO-CM04S1, a Next Generation..
28/3/202408:00GLOBEGeoVax to Present Data on GEO-CM04S1, a Next Generation..
12/3/202408:00GLOBEGeoVax to Present at the 36th Annual Roth Conference
11/3/202415:13EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
10/3/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
06/3/202408:00GLOBEGeoVax Achieves Milestone in Transition to Commercially..
01/3/202415:08EDGAR2Form S-3 - Registration statement under Securities Act of..
29/2/202415:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202415:00GLOBEGeoVax Reports 2023 Year-End Financial Results and Provides..
22/2/202415:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202408:00GLOBEGeoVax to Report 2023 Financial Results and Provide..
19/2/202408:00GLOBEGeoVax to Present at the 2024 BIO CEO & Investor Conference
16/2/202415:01EDGAR2Form 8-K - Current report
14/2/202414:38EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13/2/202408:00GLOBEGeoVax Announces Multiple Patent Issuances and Allowances
07/2/202415:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202408:00GLOBEGeoVax Reports Positive Interim Data From Phase 2 Clinical..
31/1/202412:13EDGAR2Form 8-K - Current report
29/1/202408:00GLOBEGeoVax Announces 1-for-15 Reverse Stock Split to Regain..
16/1/202415:03EDGAR2Form 8-K - Current report
12/1/202415:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/1/202408:00GLOBEGeoVax Appoints Dr. Marc Pipas as Executive Medical..
04/1/202408:00GLOBEGeoVax Announces Gedeptin® Patient Enrollment Closure for..
03/1/202408:00GLOBEGeoVax Announces Issuance of Malaria Vaccine Patent
02/1/202415:10EDGAR2Form S-1 - General form for registration of securities under..
27/12/202308:00GLOBEGeoVax to Present at Biotech Showcase During J.P. Morgan..
26/12/202314:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202308:00GLOBEGeoVax Expands Rights Under NIH COVID-19 License to Include..
08/12/202315:02EDGAR2Form 8-K - Current report
04/12/202307:00EDGAR2Form 8-K - Current report
30/11/202315:30GLOBEGeoVax Hemorrhagic Fever Vaccine Data Presented at World..
29/11/202308:00GLOBEGeoVax to Participate in Upcoming December Investor Events
28/11/202308:00GLOBEGeoVax COVID-19 Vaccine Clinical Data Presented at World..
27/11/202315:06EDGAR2Form DEF 14A - Other definitive proxy statements
17/11/202315:27EDGAR2Form PRE 14A - Other preliminary proxy statements
14/11/202308:00GLOBEProgress on GeoVax’s Universal Coronavirus Vaccine..
09/11/202311:40EDGAR2Form 8-K - Current report
08/11/202315:04EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/11/202315:03EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/11/202315:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/11/202315:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202315:00GLOBEGeoVax Reports Third Quarter 2023 Financial Results and..
31/10/202308:00GLOBEGeoVax to Report Third Quarter 2023 Financial Results and..
30/10/202308:00GLOBEGeoVax Commences Site Expansion for Phase 2 Trial of..
25/10/202308:00GLOBEGeoVax to Participate in Upcoming November Investor and..
24/10/202308:00GLOBEGeoVax Update: Clinical and Operational Progress Toward..
09/10/202308:00GLOBEGeoVax Receives Notice of Allowance for Marburg Vaccine..
05/10/202308:00GLOBEGeoVax Receives Notice of Allowance for HIV Vaccine Patent
27/9/202315:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/9/202308:00GLOBEGeoVax to Participate in Upcoming October Investor and..

Su Consulta Reciente

NASDAQ
GOVX
GeoVax Labs
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados